



# AF•B STEP



www.afbstep.eu

## Redefining **Atrial Fibrillation (AF)** from YES or NO to what really matters



### Why it matters

- Atrial fibrillation (AF) affects 1 in 3 people by age 55
- Major cause of stroke, heart failure, and early death
- Current diagnostic procedure too simplistic (yes / no)

### What we do

- Analyse data from >100,000 individuals
- Improve how AF is measured, quantified, and treated
- Set standards for AF measurement via medical devices and wearables

### Impact

- Better clinical decisions
- Improved patient outcomes
- Reduced healthcare burden



*“We quantify the burden of AF to improve screening, treatment, and health policy”*

**Duration:** 4 years  
**Start:** January 2026  
**Industry funding:** € 9.56 Mio  
**EU funding:** € 8.15 Mio  
**Consortium:** 18 partners




**Coordination:** Prof. Paulus Kirchhof, Universitätsklinikum Hamburg-Eppendorf, Germany

**Project Lead:** Dr. Mirko de Melis, Medtronic Bakken Research Center B.V., The Netherlands

[info@afbstep.eu](mailto:info@afbstep.eu)

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101252780. The JU receives support from the European Union's Horizon Europe research and innovation programme, COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and from consortium partners Acesion Pharma ApS, Medical Algorithmics, Preventicus GmbH, Thryv Therapeutics Inc. and Withings. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.



Hand: © anyaberkut | istockphoto.com Composition: © Alexander Hettich | alpha01.de